-1 	|BT| (S (NP (NP (NP (NN Overexpression) (NN progastrin)) (, ,) (NP (JJ nonamidated) (ADJP (RB incompletely) (VBN processed)) (NN product) (NN gastrin) (NN gene)) (, ,)) (VP (VBN shown) (VP (VBP induce) (NP (JJ colonic) (NN hyperproliferation))))) (VP (VBP promote) (NP (NP (JJ colorectal) (NN cancer) (NN mouse)) (, ,) (NP (NP (NN mechanism) (NN pathogenesis)) (VP (VBN defined)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 7:D12.776 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 46:A03.556.124.526.356 199:D06.472.317.413 200:D06.472.317.413|ES| 2:1 9:1 17:1 18:1 19:1 52:1 162:1 237:1 243:1 501:1 668:1 671:1 672:1 673:1 674:1 675:1 676:1 677:1 678:1 679:1 680:1
-1 	|BT| (S (NP (NN p53) (NN activation) (NN CRC) (NN cell)) (VP (VBD interfered) (NP (JJ IL-6-induced) (NN invasion) (NN migration)) (PP (IN via) (NP (JJ miR-34a-dependent) (NN downregulation) (NN IL6R) (NN expression))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 41:A11 85:G02.111.087.225 201:D12.644.276.374.465.224|ES| 12:1 19:1 94:1 115:1 225:1 245:1 514:1 595:1 596:1 620:1 681:1 682:1 683:1 684:1
-1 	|BT| (S (NP (NN Penta-1,2,3,4,6-O-galloyl-beta-D-glucose)) (VP (VP (VBZ induces) (SBAR (S (NP (NN p53)) (VP (VBZ inhibits) (NP (NN STAT3) (NN prostate) (NN cancer) (NN cell) (NN vitro)))))) (VP (VBZ suppresses) (NP (NN prostate) (NN xenograft) (NN tumor) (NN growth)) (FW vivo)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 45:G07.700.320.249 82:D12.644.360.024.342.300 91:D09.546.359.448 92:E04.936.764 93:A01.941.875 122:C14.280.383 202:C04.588.945.440.770|ES| 7:1 12:1 18:1 19:1 77:1 94:1 102:1 214:1 216:1 251:1 265:1 378:1 615:1 685:1 686:1
-1 	|BT| (NP (NP (NN PURPOSE) (CC AND) (JJ EXPERIMENTAL) (NN DESIGN)) (: :) (NP (NP (DT The) (JJ molecular) (NN mechanism) (NN p14ARF) (NN gene)) (ADJP (JJ altered) (SBAR (S (NP (NP (JJ non-small) (NN cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-))) (VP (NN complex) (ADJP (JJ unclear)))))))) |ET| |BS|110:C04.588.894.797.520.109.220.249 203:G05.360.340.024.340.375.249.375 204:E05.581.500 205:E05.581.500|ES| 9:1 10:1 14:1 18:1 19:1 94:1 104:1 161:1 162:1 328:1 329:1 443:1 687:1 688:1 689:1 690:1 691:1 692:1 693:1 694:1 695:1
-1 	|BT| (NP (NP (NP (NN PURPOSE) (: :)) (NN IFITM3) (, ,) (JJ IFN-inducible) (NN gene)) (, ,) (NP (VBN overexpressed) (JJ human) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 55:B01.050.150.900.649.801.400.112.400.400|ES| 2:1 9:1 17:1 18:1 19:1 25:1 36:1 104:1 687:1 696:1 697:1
-1 	|BT| (S (NP (NN PURPOSE) (: :)) (NP (DT The) (NN MYC) (NN oncogene)) (ADVP (RB frequently)) (VP (VBN overexpressed) (NP (NN prostate) (NN cancer)))) |ET| |BS||ES| 18:1 19:1 24:1 25:1 77:1 104:1 472:1 687:1 691:1 698:1
-1 	|BT| (NP (NP (NN Regulation) (NN tumor) (NN suppressor) (NN homeogene) (NN Cdx2) (NN HNF4alpha) (JJ intestinal) (NN cancer))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 101:C04.588.274.476.411 142:I01.880.604 206:G05.360.340.024.340.375.249|ES| 7:1 18:1 19:1 109:1 123:1 213:1 699:1 700:1 701:1
-1 	|BT| (FRAG (NP (NNS Results)) (VBP show) (NP (NN KLF9) (JJ haploinsufficient) (NN suppressor) (NN colon) (NN tumorigenesis) (NN Apc)) (-LRB- -LRB-) (NP (NP (NP (NP (NN Min)) (: /) (CC +) (-RRB- -RRB-) (NN mouse) (NN part)) (, ,) (NP (NP (NN repression) (NN ISG15) (NN latter) (POS 's)) (JJ antiapoptotic) (NN function))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 38:Z01.058.290.120.180 40:Z01.542.248.700 46:A03.556.124.526.356 207:G05.365.590.029.530.587 208:F01.393.821|ES| 2:1 10:1 14:1 19:1 33:1 52:1 78:1 113:1 280:1 429:1 451:1 461:1 700:1 702:1 703:1 704:1 705:1 706:1 707:1 708:1 709:1
-1 	|BT| (S (NP (NNS RESULTS) (: :)) (VP (ADVP (RB Herein)) (VB provide) (NP (JJ new) (NP (NN evidence) (JJ transcriptional) (NN regulation)) (NN Notch) (NN PEA3) (NN breast) (NN cancer)))) |ET| |BS|142:I01.880.604 209:G02.111.087.847|ES| 18:1 19:1 23:1 38:1 104:1 256:1 428:1 438:1 559:1 710:1 711:1 712:1 713:1
-1 	|BT| (NP (NP (NNS RESULTS) (: :)) (S (PP (IN In) (NP (NN CRC) (NN cell) (NN line))) (, ,) (VP (VBP mimic) (NP (NN miR-221) (NN miR-222) (VBD activated) (NN NF-kappaB) (NN STAT3)) (, ,) (NP (VBG increasing) (NN expression) (NN miR-221) (NN miR-222))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 82:D12.644.360.024.342.300 94:A11.251.210 210:D12.776.260.600|ES| 2:1 19:1 94:1 104:1 115:1 140:1 141:1 163:1 244:1 245:1 251:1 264:1 567:1 710:1 714:1 715:1
-1 	|BT| (S (NP (NN Sil) (NN gene) (NN expression) (NN lung) (NN cancer)) (VP (VBD correlated) (NP (NN expression) (JJ several) (NN kinetochore) (NN check-point) (NN gene) (JJ histopathologic) (JJ mitotic) (NN index)))) |ET| |BS|155:G05.355.310 211:A11.284.430.106.279.345.190.160.165.500 212:E01.370.225.500.385.500|ES| 9:1 18:1 19:1 115:1 262:1 328:1 446:1 716:1 717:1 718:1 719:1 720:1 721:1
-1 	|BT| (S (NP (NN Silencing) (NN MLH1)) (VP (ADVP (RB frequently)) (VBN seen) (S (NP (JJ sporadic) (JJ colorectal) (NN cancer))))) |ET| |BS|4:C04.588.274.476.411.307 213:F02.830.816.964|ES| 17:1 18:1 19:1 698:1 722:1 723:1 724:1 725:1
-1 	|BT| (S (ADVP (RB Similarly)) (, ,) (NP (NN treatment) (JJ human) (NN colon) (NN cancer) (NN cell) (NN line) (NN hypomethylating) (NN agent)) (VP (VBZ induces) (NP (NP (JJ differentiation-related) (NN gene)) (, ,) (PP (VBG including) (NP (NN CDX1)))))) |ET| |BS|6:G05.360.340.024.340 52:E02 55:B01.050.150.900.649.801.400.112.400.400 74:G04.299.151 94:A11.251.210|ES| 2:1 9:1 18:1 19:1 36:1 94:1 113:1 214:1 264:1 546:1 561:1 726:1 727:1 728:1 729:1 730:1
-1 	|BT| (S (NP (JJ Sonic) (NN hedgehog) (NN inhibitor)) (VP (VBP prevent) (NP (JJ colitis-associated) (NN cancer)) (FRAG (IN via) (NP (VBN orchestrated) (NN mechanism) (NN IL-6)) (: /) (NP (NP (NN gp130) (NN inhibition)) (, ,) (NP (NN 15-PGDH) (NN induction)) (, ,) (NP (NN Bcl-2) (NN abrogation)) (, ,) (NP (NN tumorsphere) (NN inhibition)))))) |ET| |BS|43:F01.145.544 53:C06.405.205.265 54:G05.360.340.024.340.375.500.791.150 201:D12.644.276.374.465.224 214:B01.050.150.900.649.473.376|ES| 2:1 18:1 19:1 103:1 133:1 158:1 162:1 380:1 410:1 596:1 731:1 732:1 733:1 734:1 735:1 736:1 737:1 738:1
-1 	|BT| (S (NP (NN SPDEF)) (VP (VP (VBD inhibited) (NP (NN expression) (JJ beta-catenin-target) (NN gene) (NN mouse) (NN colon) (NN tumor))) (, ,) (VP (VBD interacted) (NP (NP (NN beta-catenin) (NN block) (JJ transcriptional) (NN activity)) (NP (NN CRC) (NN cell) (NN line))) (, ,) (S (VP (VBG resulting) (NP (JJR lower) (NN level) (NN cyclin) (NN D1) (NN c-MYC))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 51:C04.588.274.476.411.307.180 94:A11.251.210 122:C14.280.383 155:G05.355.310 209:G02.111.087.847 215:D12.644.360.262.150.100|ES| 2:1 7:1 9:1 19:1 52:1 60:1 94:1 113:1 115:1 117:1 245:1 249:1 264:1 365:1 384:1 399:1 559:1 625:1 739:1 740:1 741:1 742:1 743:1 744:1
-1 	|BT| (S (NP (JJ Stable) (NN transfection) (NN Ha-ras) (JJ human) (NN colon) (NN cancer) (NN line) (NN CaCo2)) (VP (VBP result) (NP (JJ morphologic) (NN differentiation) (JJ small) (NN bowel) (NN phenotype)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 55:B01.050.150.900.649.801.400.112.400.400 74:G04.299.151 80:G05.695 216:Z01.107.084.900.425 217:E05.393.350.810 218:A03.556.124.684|ES| 18:1 19:1 36:1 101:1 113:1 215:1 236:1 264:1 745:1 746:1 747:1 748:1 749:1 750:1 751:1
-1 	|BT| (NP (NP (NP (DT The) (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-) (NN gene) (NN product)) (NP (VBN mutated) (JJ vast) (NN majority) (JJ human) (JJ colorectal) (NN cancer)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 219:G05.360.340.024.340.375.249.320 220:D05.500.117.249|ES| 9:1 10:1 11:1 14:1 17:1 18:1 19:1 36:1 57:1 58:1 59:1 198:1 229:1 675:1 691:1 752:1
-1 	|BT| (S (NP (DT The) (NN adhesion) (NN molecule) (NN L1CAM)) (VP (VBZ mediates) (S (NP (NN chemoresistance) (NN migration) (NN tumor) (NN cell) (JJ elevated) (NN CRC) (NN tissue)) (NP (VBN associated) (JJ metastatic) (NN spread) (JJ poor) (NN prognosis) (NN patient))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 98:A10 113:C04.697.650 159:I01.880.735.634 163:E01.789 221:D12.776.395.550.200.250.520.578 222:D12.776.395.550.200|ES| 7:1 19:1 94:1 120:1 169:1 180:1 182:1 245:1 272:1 337:1 514:1 544:1 545:1 691:1 753:1 754:1 755:1 756:1 757:1
-1 	|BT| (S (NP (DT The) (NN analysis) (JJ clinical) (JJ characteristic)) (VP (VBD showed) (SBAR (S (NP (NN miR-141)) (ADVP (RB significantly)) (VP (VBD downregulated) (NP (NN tissue) (NN cell) (NN line) (JJ pancreatic) (NN cancer))))))) |ET| |BS|94:A11.251.210 98:A10|ES| 18:1 19:1 84:1 94:1 124:1 132:1 264:1 272:1 336:1 426:1 463:1 467:1 661:1 691:1
-1 	|BT| (S (NP (DT The) (JJ apoptosis-inducing) (NN effect) (NN gastrin) (JJ colorectal) (NN cancer) (NN cell)) (VP (VBZ relates) (NP (NP (VBN increased) (NP (NN IEX-1)) (NN expression)) (VP (VBG mediating) (NP (NP (NN NF-kappa) (NN B)) (NN inhibition)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 39:G04.299.139.160 41:A11 43:F01.145.544 199:D06.472.317.413 200:D06.472.317.413 210:D12.776.260.600|ES| 17:1 18:1 19:1 47:1 75:1 94:1 103:1 115:1 676:1 691:1 758:1 759:1 760:1 761:1 762:1 763:1
-1 	|BT| (S (NP (DT The) (NN CDX2) (NN expression) (JJ gastric) (NN cancer)) (ADVP (RB also)) (ADVP (RB inversely)) (VP (VBD correlated) (NP (NN expression) (JJ gastric) (NN mucin)))) |ET| |BS|72:D12.776.395.560.631.100|ES| 5:1 18:1 19:1 86:1 114:1 115:1 209:1 418:1 446:1 691:1
-1 	|BT| (NP (NP (DT The) (NN ECM-modulator) (NN inter)) (: -) (S (NP (NP (NN alpha-trypsin) (NN inhibitor) (JJ heavy) (NN chain) (NN family) (NN member)) (CD five) (-LRB- -LRB-) (NN ITIH5) (-RRB- -RRB-)) (ADVP (RB recently)) (VP (VBD identified) (NP (NP (NN tumor) (NN suppressor)) (VP (ADVP (RB potentially)) (VP (VBN involved) (NP (NP (VBG impairing) (NN breast) (NN cancer) (NN progression) (JJ molecular) (NN mechanism)) (VP (VBG underlying) (S (NP (NN function)) (ADJP (ADVP (RB still)) (JJ elusive))))))))))) |ET| |BS|16:C23.550.291.656 44:F01.829.263 206:G05.360.340.024.340.375.249 223:A11.284.295.310|ES| 7:1 10:1 14:1 18:1 19:1 23:1 33:1 48:1 97:1 161:1 162:1 380:1 435:1 623:1 691:1 700:1 764:1 765:1 766:1 767:1 768:1 769:1 770:1 771:1 772:1 773:1 774:1 775:1 776:1 777:1
-1 	|BT| (S (NP (DT The) (NN effect) (NN folate) (NN transporter) (NN gene) (NN ablation) (NN colon) (NN carcinogenesis)) (VP (VBD evaluated) (NP (NP (CD 8) (CD 38) (NN week)) (JJ post-azoxymethane) (NN injection) (JJ wild-type) (JJ heterozygous) (NN mouse)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 157:G05.380.383 224:D03.438.733.631.400 225:E05.337 226:E02.319.267.530 227:D12.776.157.530|ES| 8:1 9:1 19:1 52:1 75:1 91:1 113:1 207:1 691:1 778:1 779:1 780:1 781:1 782:1 783:1 784:1 785:1 786:1
-1 	|BT| (FRAG (NP (NP (DT The) (NN level) (NN miR-221) (NN miR-222)) (RRC (ADVP (RB well)) (NP (NP (NN RelA)) (, ,) (NP (NN STAT3)) (, ,) (NP (NP (NN PDLIM2) (NNS mRNAs)) (VP (VBN measured) (NP (CD 57) (JJ paired) (NN CRC) (JJ adjacent) (JJ nontumor) (NN tissue) (NN patient)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 82:D12.644.360.024.342.300 98:A10 111:D13.444.735.544 228:E05.978|ES| 2:1 19:1 120:1 126:1 140:1 141:1 245:1 249:1 250:1 251:1 272:1 326:1 445:1 447:1 691:1 787:1 788:1 789:1 790:1
-1 	|BT| (NP (NP (DT The) (NN role) (NN KCNQ1) (NN mouse) (JJ human) (JJ gastrointestinal) (NN cancer))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 55:B01.050.150.900.649.801.400.112.400.400|ES| 18:1 19:1 31:1 36:1 52:1 183:1 691:1 791:1
-1 	|BT| (S (NP (DT These) (NNS data)) (VP (VP (VBP provide) (NP (NN evidence) (NN Cdx2) (VP (VBZ antagonizes) (NP (NN process) (NN tumor) (NN cell) (NN dissemination))))) (, ,) (VP (VBP suggest) (SBAR (S (NP (NN homeobox) (NN gene)) (VP (MD might) (VP (VB represent) (NP (JJ new) (JJ therapeutic) (NN target) (JJ metastatic) (NN spreading) (NN colon) (NN cancer))))))))) |ET| |BS|8:C04 52:E02 229:G05.360.340.024.340.230.500 230:G04|ES| 2:1 7:1 9:1 18:1 19:1 38:1 94:1 113:1 160:1 213:1 337:1 541:1 638:1 711:1 712:1 792:1 793:1 794:1 795:1 796:1 797:1 798:1 799:1 800:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP suggest) (NP (S (NP (NN K-sam) (NN overexpression)) (VP (VBN associated) (NP (JJ malignant) (NN phenotype) (JJ undifferentiated) (NN type) (NN stomach) (NN cancer)))) (, ,) (NP (JJ infiltrative) (NN growth) (NN metastasis)))))) |ET| |BS|45:G07.700.320.249 80:G05.695 113:C04.697.650 231:C04.557.465.625.600.380.590 232:D02.886.030.676.180|ES| 2:1 18:1 19:1 101:1 102:1 152:1 169:1 236:1 543:1 792:1 796:1 801:1 802:1 803:1 804:1 805:1 806:1
-1 	|BT| (S (S (NP (DT This) (JJ K-Ras) (NN tumor) (NN phenotype)) (VP (VBN associated) (VP (VBD attenuated) (NP (NN signaling) (NN MAPK) (NN pathway))))) (, ,) (NP (JJ human) (NN colon) (NN cancer) (NN cell)) (VP (VBG expressing) (NP (NP (JJ mutant) (NN K-Ras) (JJ hypersensitive) (NN inhibition) (NN Raf)) (, ,) (NP (NN Mek))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 41:A11 43:F01.145.544 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 80:G05.695 233:D08.811.913.696.620.682.700.565 234:D08.811.913.696.620.682.700.565|ES| 2:1 7:1 13:1 18:1 19:1 36:1 94:1 103:1 113:1 169:1 195:1 236:1 383:1 807:1 808:1 809:1 810:1 811:1 812:1 813:1 814:1
-1 	|BT| (S (NP (DT This) (NN study)) (VP (VBZ provides) (SBAR (S (NP (NP (JJ first) (JJ quantitative) (NN analysis) (JJ discrete) (NN CRKI) (NN CRKII) (NN protein) (NNS isoforms)) (SBAR (S (NP (JJ human) (NN lung) (NN tumor)) (VP (VBZ provides) (NP (NN evidence) (NN C-CRK) (NN proto-oncogene)))))) (VP (MD may) (VP (VB foment) (NP (JJ aggressive) (NN phenotype) (NN lung) (NN cancer)))))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 80:G05.695 162:F01.145.126.125 235:G05.360.340.024.340.375.500.791 236:D12.644.360.024.318 237:C04.588.894.797.520 238:D12.776.800|ES| 4:1 7:1 18:1 19:1 36:1 38:1 131:1 236:1 328:1 491:1 538:1 563:1 661:1 807:1 815:1 816:1 817:1 818:1 819:1 820:1 821:1 822:1 823:1
-1 	|BT| (S (NP (DT This) (NN study)) (VP (VBP show) (SBAR (S (NP (NN c-Myc) (JJ critical) (JJ Apc-dependent) (JJ intestinal) (NN tumorigenesis) (NN mouse)) (VP (VBZ provides) (NP (JJ potential) (JJ therapeutic) (NN target) (NN treatment) (JJ colorectal) (NN cancer))))))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 47:A03.556.124 52:E02|ES| 17:1 18:1 19:1 52:1 78:1 109:1 131:1 160:1 429:1 541:1 546:1 807:1 815:1 824:1 825:1 826:1 827:1
-1 	|BT| (S (S (S (VP (TO To) (VP (VB understand) (NP (NN miR-141))))) (VP (VBZ mediates) (NP (NN phenotype) (JJ pancreatic) (NN cancer) (NN cell)))) (S (, ,) (NP (NNS bioinformatics) (NN tool)) (VP (VBN used) (VP (VBP identify) (NP (NN MAP4K4) (JJ potential) (NN target) (NN miR-141)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 80:G05.695 239:F02.463.188.357 240:H01.158.273.180|ES| 2:1 18:1 19:1 94:1 160:1 236:1 463:1 465:1 467:1 476:1 755:1 827:1 828:1 829:1 830:1 831:1 832:1

-1 	|BT| (FRAG (PP (TO To) (NP (VB investigate) (NP (NP (NN role) (NN KCNQ1) (JJ human) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (, ,) (NP (NP (VBN measured) (NN protein) (NN level) (NN KCNQ1) (NN immunohistochemistry) (NN tissue) (NNS microarrays)) (VP (VBG containing) (NP (NP (NN sample) (NN CRC) (NN patient) (NN liver) (NN metastasis)) (VP (VBN undergone) (NP (JJ hepatic) (NN resection))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 38:Z01.058.290.120.180 40:Z01.542.248.700 50:M01.643 55:B01.050.150.900.649.801.400.112.400.400 98:A10 113:C04.697.650 143:E01.370.225.500.607.512 228:E05.978 241:D12.776.157.530.400.600.900.124.249.500 242:A03.620|ES| 2:1 4:1 10:1 14:1 17:1 18:1 19:1 31:1 36:1 120:1 128:1 245:1 249:1 272:1 286:1 459:1 789:1 791:1 806:1 828:1 833:1 834:1 835:1 836:1 837:1 838:1

-1 	|BT| (NP (NP (NP (JJ Transient) (JJ stable) (NN overexpression) (NN mir-660)) (S (VP (VBG using) (S (NP (NN miRNA)) (VP (VBP mimic) (SBAR (S (NP (VBN reduced) (NP (NN migration)) (, ,) (NP (NN invasion)) (, ,) (NP (NN proliferation) (NN property))) (VP (VBD increased) (NP (NP (NN apoptosis) (NN p53) (JJ wild-type) (NN lung) (NN cancer) (NN cell)) (PRN (-LRB- -LRB-) (NP (NP (NN NCI-H460)) (, ,) (NP (NN LT73)) (, ,) (NP (NN A549))) (-RRB- -RRB-)))))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 39:G04.299.139.160 41:A11 120:I01.409.418.750.600.480.150 184:D13.150.650.319|ES| 2:1 8:1 10:1 12:1 14:1 18:1 19:1 47:1 89:1 94:1 152:1 299:1 328:1 350:1 360:1 363:1 364:1 373:1 452:1 514:1 567:1 620:1 839:1 840:1 841:1 842:1

-1 	|BT| (S (NP (PRP We)) (VP (VBD aimed) (VP (VB investigate) (SBAR (IN whether) (S (NP (NN Notch1) (NN signaling)) (VP (VBZ contributes) (NP (NN carcinogenesis) (JJ gastric) (NN cancer) (NN CD133) (NN induction)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 69:G02.111.087.800|ES| 18:1 19:1 86:1 195:1 207:1 221:1 459:1 651:1 652:1 736:1 843:1 844:1 845:1

-1 	|BT| (S (NP (PRP We)) (VP (VBD examined) (NP (JJ biological) (NN function) (NP (NP (JJ related) (JJ molecular) (NN mechanism) (NN PAX5) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-)))))) |ET| |BS|104:C04.557.470.200.025.255 141:G16.100 243:D12.776.260.645.500|ES| 10:1 14:1 19:1 33:1 161:1 162:1 303:1 304:1 324:1 419:1 440:1 441:1 843:1 846:1

-1 	|BT| (S (NP (PRP We)) (VP (VBD examined) (NP (NN apobec-1) (NN gene) (NN expression) (JJ human) (JJ gastrointestinal) (NN tumor) (NN colon) (JJ cancer-derived) (NN cell) (NN line)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 155:G05.355.310 244:C04.588.274.476|ES| 7:1 9:1 19:1 36:1 94:1 113:1 115:1 183:1 264:1 324:1 843:1 847:1 848:1

-1 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NP (NN rat) (NN model)) (VP (VBG carrying) (NP (JJ knockout) (NN allele) (NN gatekeeper) (NN gene) (NNP Adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN Apc) (-RRB- -RRB-)))) (VP (VBZ recapitulates) (NP (NP (JJ familial) (NN colon) (NN cancer)) (JJ human) (S (ADVP (RB closely)) (VP (VBG existing) (NP (JJ murine) (NN model)))))))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 21:G05.360.340.024.340.375.249.050 44:F01.829.263 55:B01.050.150.900.649.801.400.112.400.400 77:G05.360.340.024.340.030 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 247:G01.374.676.530 248:E05.393.335.750|ES| 9:1 10:1 14:1 18:1 19:1 36:1 58:1 59:1 71:1 72:1 113:1 221:1 230:1 280:1 403:1 627:1 843:1 849:1 850:1 851:1 852:1 853:1 854:1 855:1 856:1

-1 	|BT| (S (NP (PRP We)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NN microRNA) (NN miR-221) (NN miR-222)) (VP (VBP regulate) (NP (NP (NP (NN NF-kappaB) (NN signal) (NN transducer) (NN activator) (NN transcription) (CD 3)) (PRN (-LRB- -LRB-) (NP (NN STAT3)) (-RRB- -RRB-))) (NP (NN activation) (JJ human) (NN CRC) (NN cell) (NN line)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 184:D13.150.650.319 210:D12.776.260.600 249:G05.355.315.800 250:E07.305.812|ES| 10:1 14:1 19:1 36:1 94:1 140:1 141:1 221:1 225:1 245:1 251:1 264:1 403:1 487:1 714:1 843:1 857:1 858:1 859:1 860:1 861:1 862:1

-1 	|BT| (S (NP (PRP We)) (VP (VBD wanted) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (JJ genetic) (NN defect) (JJ relevant) (JJ colorectal) (NN cancer)) (, ,) (NP (NN Msh2) (NN p53) (NN deficiency)) (, ,)) (VP (MD would) (VP (VB influence) (NP (NN efficiency) (NN sulindac) (NN chemoprevention) (NN increase) (NN side) (NN effect))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 87:C18.654.521 251:D02.455.426.559.847.486.875 252:F02.784.692.351 253:E02.319.162 254:C16.131|ES| 2:1 12:1 17:1 18:1 19:1 40:1 74:1 75:1 221:1 253:1 585:1 588:1 843:1 863:1 864:1 865:1 866:1 867:1 868:1 869:1 870:1 871:1

-1 	|BT| (S (NP (NP (NP (NN Western) (NN blot) (JJ quantitative) (JJ real-time) (NN PCR)) (PRN (-LRB- -LRB-) (NP (NN qRT-PCR)) (-RRB- -RRB-))) (NN analysis)) (VP (VBD revealed) (SBAR (S (NP (NN MAP4K4) (NN expression)) (VP (ADVP (RB inversely)) (VBD correlated) (NP (NN miR-141) (NN expression) (JJ pancreatic) (NN cancer) (NN sample) (NN cell) (NN line))))))) |ET| |BS|94:A11.251.210 255:E05.196.401.143 256:E05.196.401.143 257:E05.393.620.500.706|ES| 10:1 14:1 18:1 19:1 94:1 115:1 264:1 275:1 418:1 446:1 463:1 465:1 467:1 661:1 817:1 835:1 872:1 873:1 874:1 875:1 876:1

-1 	|BT| (S (NP (NN Western) (NN blot)) (VP (VBD revealed) (NP (NP (NN overexpression) (NN beta-catenin)) (, ,) (NP (NP (NN c-Myc)) (, ,) (NP (NN cyclin) (NN D1)) (, ,) (NP (JJ inducible) (JJ nitric) (NN oxide) (NN synthase)) (NP (NN cyclooxygenase-2) (NN colon) (NN tumor) (NN sample)))))) |ET| |BS|22:D08.811.682.664.500.772.500 23:D12.776.091.249 24:D08.811.600.720.750 51:C04.588.274.476.411.307.180 215:D12.644.360.262.150.100 255:E05.196.401.143|ES| 2:1 7:1 19:1 60:1 61:1 63:1 64:1 65:1 66:1 113:1 152:1 275:1 743:1 744:1 824:1 835:1 872:1 873:1

-1 	|BT| (S (NP (NN Wnt/beta-catenin) (NN signaling) (JJ critical) (JJ intestinal) (NN cell) (NN proliferation)) (, ,) (VP (VBD decreased) (NP (NN CDX2) (NN expression) (NN influence) (NN Wnt) (JJ signaling-related) (NN gene) (NN progression) (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 16:C23.550.291.656 47:A03.556.124 69:G02.111.087.800 105:G02.149.115.800.925 183:G04.299.233.750|ES| 2:1 9:1 17:1 18:1 19:1 48:1 94:1 109:1 114:1 115:1 195:1 202:1 299:1 302:1 825:1 867:1 877:1 878:1

-1 	|BT| (S (NP (NN YY1)) (VP (VBZ promotes) (NP (NP (NN colon) (NN cancer) (NN growth)) (VP (VBG inhibiting) (NP (NP (NN p53)) (S (VP (VBG promoting) (NP (NN Wnt) (NN signaling) (NN pathway) (NN serf) (JJ independent) (JJ prognostic) (NN biomarker) (NN CRC) (NN patient))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 45:G07.700.320.249 50:M01.643 122:C14.280.383 147:G02.149.115.800.925 158:D23.101 258:D12.776.260.235.875|ES| 12:1 18:1 19:1 102:1 113:1 120:1 195:1 245:1 298:1 383:1 877:1 879:1 880:1 881:1 882:1 883:1 884:1 885:1

1 	|BT| (S (NP (NN SMO)) (VP (MD might) (NP (NP (JJ good) (JJ therapeutic) (NN target) (NN patient)) (NP (JJ colorectal) (NN polyp) (NN carcinoma))) (, ,) (NP (RB even) (NN absence) (NN Hh) (NN signal) (NN activation)))) |ET| |BS|50:M01.643 52:E02 265:C04.557.470.200 444:C23.300.825|ES| 2:1 17:1 19:1 120:1 160:1 225:1 304:1 541:1 647:1 798:1 859:1 1268:1 1270:1 1318:1 1533:1 1534:1

1 	|BT| (S (NP (NN SPOCK1) (NN act) (NN oncogene)) (VP (MD may) (NP (NP (JJ prognostic) (NN factor) (JJ therapeutic) (NN target) (NN patient)) (NP (NNP GBC))))) |ET| |BS|9:G05.360.340.024.340.375.500 50:M01.643 52:E02 81:E02.095.465.425.400.330.050.400|ES| 19:1 24:1 120:1 160:1 185:1 246:1 491:1 541:1 884:1 1535:1 1536:1

1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (NNS data)) (VP (VBD suggested) (SBAR (S (NP (NN ING5) (NN downregulation)) (VP (MD might) (VP (VBN involved) (SBAR (S (NP (NP (NN carcinogenesis)) (, ,) (NP (NN growth)) (, ,) (NP (NN invasion) (NN lung) (NN cancer))) (VP (MD could) (VP (VBN considered) (S (NP (JJ promising) (NN marker) (NN gauge) (NN aggressiveness) (NN lung) (NN cancer))))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 45:G07.700.320.249 85:G02.111.087.225 158:D23.101 162:F01.145.126.125|ES| 2:1 18:1 19:1 102:1 207:1 328:1 534:1 595:1 620:1 774:1 793:1 798:1 908:1 925:1 1061:1 1316:1 1517:1 1537:1 1538:1 1539:1 1540:1

1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBG finding) (SBAR (S (NP (JJ indicated) (NN PVT1/EZH2/LATS2) (NN interaction)) (VP (MD might) (VP (VB serve) (NP (JJ new) (NN target) (NN lung) (NN adenocarcinoma) (NN diagnosis) (NN therapy)))))))) |ET| |BS|52:E02 263:E01|ES| 2:1 19:1 130:1 160:1 255:1 328:1 532:1 618:1 712:1 798:1 927:1 1037:1 1537:1 1538:1 1541:1 1542:1

1 	|BT| (S (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (VP (VBP result) (SBAR (S (NP (VBN demonstrated) (JJ first) (NN time) (NN miR-372)) (VP (VBZ suppresses) (NP (NN tumorigenesis) (NN development) (NN EC))))))) (: ;) (FRAG (NP (NP (NN RhoC)) (JJ new) (ADJP (RB potentially) (JJ important)) (JJ therapeutic) (NN target)))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 52:E02 322:G01.910|ES| 2:1 19:1 35:1 78:1 101:1 160:1 217:1 541:1 686:1 712:1 773:1 816:1 902:1 1081:1 1175:1 1537:1 1538:1 1543:1 1544:1 1545:1

1 	|BT| (S (NP (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (JJ present) (NN work)) (VP (VBD revealed) (NP (JJ novel) (NN function) (NN TIP30)) (, ,) (VP (ADVP (RB possibly)) (VBN used) (S (NP (JJ independent) (ADJP (JJ prognostic) (NN factor) (JJ potential)) (JJ therapeutic) (NN target) (JJ gastric) (NN cancer)))))) |ET| |BS|52:E02 259:D12.776.395.240.150.500 445:I03.946|ES| 2:1 18:1 19:1 33:1 86:1 160:1 185:1 275:1 476:1 541:1 827:1 883:1 884:1 891:1 1307:1 1537:1 1538:1 1546:1 1547:1 1548:1

1 	|BT| (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (NNS data)) (VP (VBP suggest) (SBAR (S (NP (NN SRC-3)) (VP (MD may) (NP (JJ important) (NN oncogene) (JJ therapeutic) (NN target) (NN lung) (NN cancer))))))) |ET| |BS|9:G05.360.340.024.340.375.500 52:E02|ES| 2:1 18:1 19:1 24:1 160:1 328:1 491:1 541:1 793:1 796:1 902:1 1537:1 1538:1 1549:1
1 	|BT| (S (NP (NNP TaqMan) (NN PCR) (NN genotyping) (NN technology)) (VP (VBD used) (VP (VB detect) (NP (NP (NP (NN genotype) (NN ITGA3) (NN gene) (NNS SNPs)) (PRN (-LRB- -LRB-) (NP (NP (NN rs2230392)) (, ,) (NP (NN rs2285524) (NN rs16948627))) (-RRB- -RRB-))) (NP (JJ peripheral) (NN blood)))))) |ET| |BS|6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 61:E05.318.740.600.800 225:E05.337 386:F02.463.425.069 396:G05.380 434:E05.318.308.985.525.375 446:G05.365.795.598 447:C04.557.450.565.575.650 448:E05.393.620.500 449:A12.207.152 450:J01.897|ES| 2:1 7:1 9:1 10:1 14:1 19:1 171:1 336:1 476:1 780:1 875:1 1298:1 1329:1 1476:1 1511:1 1550:1 1551:1 1552:1 1553:1 1554:1 1555:1 1556:1 1557:1 1558:1 1559:1 1560:1 1561:1 1562:1

1 	|BT| (S (NP (JJ Testis-specific) (NN Fank1) (NN gene) (JJ knockdown) (NN mouse)) (VP (VBP produce) (NP (NN oligospermia)) (PP (IN via) (NP (NN apoptosis))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 400:E05.393.335.500 451:C12.294.365.700.508 452:A05.360.444.849|ES| 9:1 19:1 52:1 89:1 464:1 596:1 1563:1 1564:1 1565:1 1566:1

1 	|BT| (S (NP (DT The) (NN aim) (NN study)) (VP (VBD determine) (SBAR (IN whether) (S (S (VP (VBG combining) (NP (NN kallistatin) (NN gene) (NN therapy) (NN meloxicam)))) (VP (MD could) (VP (VB offer) (NP (ADJP (ADJP (JJR better)) (ADJP (JJ therapeutic))) (NN effect) (NN combat) (NN HCC) (NN mouse)))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255|ES| 9:1 19:1 52:1 74:1 75:1 130:1 131:1 221:1 441:1 541:1 691:1 904:1 908:1 1042:1 1088:1 1089:1 1498:1 1567:1 1568:1

1 	|BT| (S (NP (DT The) (NN aim) (NN study)) (VP (VBP evaluate) (NP (NN hypermethylation) (JJ spastic) (NN paraplegia-20) (NN promoter) (JJ potential) (NN biomarker) (JJ prognostic) (NN factor) (JJ gastric) (NN cancer)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 158:D23.101 225:E05.337 453:C10.597.622.669|ES| 18:1 19:1 83:1 86:1 131:1 185:1 664:1 691:1 827:1 884:1 885:1 890:1 1567:1 1569:1 1570:1

1 	|BT| (S (S (NP (DT The) (NN aim) (NN work)) (VP (VP (VB evaluate) (SBAR (IN whether) (S (NP (NN TP53) (NN mutation)) (VP (VBN classified) (ADVP (RB functionally)) (ADJP (JJ inactive)))))) (PRN (-LRB- -LRB-) (NP (ADJP (ADJP (JJR <)) (CC or) (ADJP (JJ =))) (ADJP (CD 20) (NN %)) (JJ wildtype) (NN transactivation) (NN ability)) (-RRB- -RRB-))) (S (NP (NP (JJ different) (JJ prognostic) (JJ predictive) (NN value) (NN CRC)) (VBN compared) (NN mutation)) (VP (VBD retained) (NP (JJ significant) (NN activity)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 225:E05.337 385:F02.784.629.131 395:L01.100 445:I03.946 454:G05.355.315.800|ES| 10:1 14:1 19:1 34:1 50:1 135:1 221:1 245:1 312:1 369:1 399:1 414:1 533:1 691:1 884:1 890:1 1018:1 1248:1 1300:1 1546:1 1567:1 1571:1 1572:1 1573:1 1574:1 1575:1 1576:1 1577:1

1 	|BT| (NP (NP (NP (DT The) (NN expression) (JJ gastric) (NN cancer) (NN marker) (NN MUC1)) (, ,) (NP (NN MUC2)) (, ,) (NP (NN MUC5AC)) (, ,) (NP (NN oncogene) (NN c-myc)) (, ,) (NP (NN c-met)) (, ,) (NP (NN cyclin) (NN E1)) (, ,) (NP (NN cancer) (NN stem) (NN cell) (NN marker) (NN CD44)) (VP (VBD determined) (NP (NN MGCC3I) (NN cell))))) |ET| |BS|41:A11 158:D23.101 332:A11.872.650|ES| 2:1 18:1 19:1 24:1 86:1 94:1 115:1 210:1 212:1 455:1 534:1 691:1 743:1 1106:1 1578:1 1579:1 1580:1 1581:1 1582:1 1583:1

1 	|BT| (S (NP (NP (DT The) (NN lung) (NN adenocarcinoma) (NN cell) (NN bearing) (JJ K-ras) (NN gene) (NN mutation)) (PRN (-LRB- -LRB-) (NP (NN A549) (NN H820)) (-RRB- -RRB-))) (VP (VBD showed) (NP (ADJP (RB consistently) (JJR higher)) (NN level) (NN cell) (NN motility)) (S (PP (IN without) (NP (NP (NN mutation)) (PRN (-LRB- -LRB-) (NP (NN TKB6) (NN TKB14)) (-RRB- -RRB-)))) (, ,) (NP (NN motility) (NN A549) (NN H820) (NN cell)) (ADVP (RB significantly)) (VP (VBD inhibited) (NP (NN dnAkt) (NN transfection)))))) |ET| |BS|18:G05.365.590 41:A11 122:C14.280.383 217:E05.393.350.810 455:B01.050.150.900.649.147.890|ES| 2:1 9:1 10:1 14:1 19:1 34:1 94:1 124:1 132:1 170:1 249:1 255:1 328:1 364:1 365:1 691:1 746:1 1121:1 1177:1 1195:1 1584:1 1585:1 1586:1 1587:1 1588:1 1589:1

1 	|BT| (FRAG (NP (DT The) (NN morphology) (CD eight) (NN ASPL-TFE3) (JJ fusion-positive) (JJ renal) (NN tumor)) (, ,) (PP (IN although) (NP (NP (VBG overlapping) (NN aspect) (JJ classic) (NNS ASPS)) (, ,) (VP (ADVP (RB closely)) (VBZ resembles) (NP (NP (JJ renal) (NN cell) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN RCC)) (-RRB- -RRB-)))) (, ,) (NP (FW priori) (NN diagnosis) (NN case))))) |ET| |BS|263:E01 274:C04.588.945.947.535 295:C04.557.470.200.025.390|ES| 2:1 7:1 10:1 14:1 19:1 94:1 112:1 304:1 348:1 691:1 855:1 922:1 923:1 934:1 935:1 1037:1 1413:1 1590:1 1591:1 1592:1 1593:1 1594:1 1595:1 1596:1

1 	|BT| (NP (NP (NP (DT The) (JJ recombinant) (NN plasmid)) (NP (VBN transfected) (JJ human) (ADJP (NN lung) (NN cancer) (NN A549) (NN cell) (JJ liposome-mediated)) (NN method)))) |ET| |BS|41:A11 55:B01.050.150.900.649.801.400.112.400.400 168:E05.581 456:D25.479.517 457:G05.360.600|ES| 18:1 19:1 36:1 94:1 328:1 364:1 479:1 691:1 1420:1 1597:1 1598:1 1599:1

1 	|BT| (S (NP (DT The) (JJ resultant) (NN MLL) (NN fusion) (NN protein)) (VP (VBN known) (VP (VBP mediate) (NP (NN leukaemia) (NN disruption) (JJ normal) (JJ epigenetic) (NN regulation) (NN target) (NN gene) (NN locus))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 142:I01.880.604 361:C04.557.337 458:G05.360.340.024.380|ES| 4:1 9:1 19:1 118:1 160:1 377:1 438:1 556:1 691:1 936:1 1207:1 1263:1 1600:1 1601:1 1602:1 1603:1

1 	|BT| (S (NP (NP (DT The) (JJ significant) (NN association) (NN SNIP1) (NN c-Myc) (NN staining) (JJ non-small) (NN cell) (NN lung) (NN cancer) (NN tissue) (NN array) (NN evidence) (NN activity)) (VP (MD might) (VP (VBN linked)))) (VP (VBZ suggests) (SBAR (S (NP (NN SNIP1)) (VP (MD might) (NP (JJ important) (NN modulator) (NN c-Myc) (NN activity) (NN carcinogenesis))))))) |ET| |BS|12:Z01.542.049 33:C04.697.098 98:A10 110:C04.588.894.797.520.109.220.249 386:F02.463.425.069|ES| 18:1 19:1 38:1 94:1 135:1 207:1 272:1 328:1 331:1 399:1 691:1 694:1 798:1 824:1 902:1 1298:1 1363:1 1604:1 1605:1 1606:1 1607:1

1 	|BT| (S (NP (DT The) (JJ significant) (NN link) (NN tobacco) (NN loss) (NN p16) (NN locus)) (VP (VBZ identifies) (NP (JJ additional) (JJ genetic) (NN target) (NN smoking) (NN pathogenesis) (NN lung) (NN cancer)))) |ET| |BS|203:G05.360.340.024.340.375.249.375 459:B01.650.940.800.575.100.905.900 460:B01.650.940.800.575.100.905.900 461:F01.145.958.500 462:J01.637.836|ES| 18:1 19:1 32:1 135:1 160:1 328:1 377:1 501:1 691:1 864:1 980:1 1313:1 1608:1 1609:1 1610:1 1611:1

1 	|BT| (S (NP (DT The) (JJ siRNA-mediated) (NN DEPDC1) (NN depletion)) (VP (VBD resulted) (NP (NP (JJ significant) (NN inhibition) (NN proliferation) (NN delay) (NN cell) (NN cycle) (NN progression) (NN NPC) (NN cell) (NN line)) (, ,) (NP (NN CNE-1) (NN HNE-1))))) |ET| |BS|16:C23.550.291.656 43:F01.145.544 117:D13.150.650.700 353:G04.299.134|ES| 2:1 19:1 48:1 94:1 103:1 135:1 136:1 264:1 299:1 594:1 601:1 691:1 1174:1 1612:1 1613:1 1614:1 1615:1 1616:1

1 	|BT| (NP (NP (DT The) (JJ unbalanced) (NN translocation)) (, ,) (NP (NN der) (-LRB- -LRB-) (CD 17) (-RRB- -RRB-) (-LRB- -LRB-) (NN X) (: ;) (CD 17) (-RRB- -RRB-) (-LRB- -LRB-) (NN p11) (NN .2) (: ;) (CD q25)) (-RRB- -RRB-) (, ,) (NP (NP (JJ characteristic) (JJ alveolar) (JJ soft) (NN part) (NN sarcoma)) (PRN (-LRB- -LRB-) (NP (NN ASPS)) (-RRB- -RRB-)))) |ET| |BS|439:C04.557.450.590.775 463:C23.550.210.870|ES| 2:1 10:1 14:1 19:1 217:1 336:1 451:1 691:1 923:1 929:1 930:1 931:1 932:1 1117:1 1287:1 1524:1 1617:1 1618:1 1619:1

1 	|BT| (S (ADVP (RB Therefore)) (NP (NN bile) (NN duct) (NN cancer) (NN patient)) (VP (MD may) (NP (VBN treated) (NN miR-34a) (NN inhibitor) (NN Per1) (NN stimulator) (NN future)))) |ET| |BS|50:M01.643 52:E02 354:I01.320|ES| 18:1 19:1 120:1 380:1 491:1 1099:1 1190:1 1620:1 1621:1 1622:1 1623:1 1624:1 1625:1

1 	|BT| (S (NP (DT These) (NNS data) (NN challenge) (NN view) (NN MYH11) (NN passive) (NN differentiation) (NN marker)) (VP (VBG functioning) (S (NP (NN muscle) (NN contraction)) (VP (VBP add) (S (VP (VBG understanding) (NP (JJ intestinal) (NN neoplasia)))))))) |ET| |BS|74:G04.299.151 102:C04.588.274.476.411 158:D23.101 239:F02.463.188.357 375:Z01.639.100 464:G11.427.590.540|ES| 19:1 109:1 215:1 534:1 640:1 792:1 793:1 905:1 1371:1 1626:1 1627:1 1628:1 1629:1 1630:1 1631:1 1632:1

1 	|BT| (S (NP (DT These) (NNS data)) (VP (VP (VBP provide) (NP (NN evidence) (NN Cdx2) (VP (VBZ antagonizes) (NP (NN process) (NN tumor) (NN cell) (NN dissemination))))) (, ,) (VP (VBP suggest) (SBAR (S (NP (NN homeobox) (NN gene)) (VP (MD might) (VP (VB represent) (NP (JJ new) (JJ therapeutic) (NN target) (JJ metastatic) (NN spreading) (NN colon) (NN cancer))))))))) |ET| |BS|8:C04 52:E02 229:G05.360.340.024.340.230.500 230:G04|ES| 2:1 7:1 9:1 18:1 19:1 38:1 94:1 113:1 160:1 213:1 337:1 541:1 638:1 711:1 712:1 792:1 793:1 794:1 795:1 796:1 797:1 798:1 799:1 800:1

1 	|BT| (S (VP (DT These) (VBG finding) (VP (VBP indicate) (SBAR (S (NP (NNP BIM) (NN deletion) (NN polymorphism) (JJ common) (JJ Korean) (NN NSCLC) (NN patient)) (ADVP (RB significantly)) (VP (VBP affect) (NP (JJ intrinsic) (JJ biologic) (NN function) (JJ BH3-only) (NN protein)))))))) |ET| |BS|7:D12.776 50:M01.643 110:C04.588.894.797.520.109.220.249 306:G05.355.600.800 307:G05.365.795 433:F01.470.047 465:D23|ES| 4:1 19:1 33:1 120:1 124:1 329:1 655:1 792:1 927:1 1059:1 1060:1 1479:1 1486:1 1633:1 1634:1 1635:1 1636:1 1637:1

1 	|BT| (S (NP (DT These) (VBG finding) (NP (VBN suggested) (NN Notch1) (NN signaling))) (VP (VBP play) (NP (NP (NP (JJ important) (NN role) (NN maintenance) (NN cancer)) (JJ stem-like) (NN phenotype) (JJ diffuse) (NN type) (JJ gastric) (NN cancer) (NN RBP-Jkappa) (JJ dependent) (NN pathway)) (VP (VBG inhibiting) (NP (NN Notch1) (NN signaling)))) (VP (MD could) (NP (JJ effective) (NN therapy) (NN CD133) (JJ positive) (JJ diffuse) (NN type) (JJ gastric) (NN cancer))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 52:E02 69:G02.111.087.800 79:I03.450.642.693 80:G05.695 122:C14.280.383 188:N02.628 309:A18.024.937|ES| 18:1 19:1 31:1 86:1 130:1 195:1 233:1 236:1 238:1 321:1 383:1 543:1 651:1 652:1 653:1 792:1 880:1 902:1 908:1 925:1 927:1 1062:1 1063:1 1638:1 1639:1

1 	|BT| (NP (NP (DT These) (UCP (S (VP (VBG finding) (PP (VBN suggested) (NP (NN endostatin) (NN gene) (NN therapy))) (, ,) (S (VP (VBG using) (NP (JJ cationic) (JJ vector-mediated) (JJ intravenous) (NN gene) (NN transfer)))))) (, ,) (MD might) (NP (NP (JJ feasible) (NN strategy) (JJ organ-targeted) (NN prevention) (NN regulation)) (JJ possible) (VBN disseminated) (NN cancer))))) |ET| |BS|123:G05.360.337 142:I01.880.604 466:D12.644.276.100.450.750 467:D01.248.497.300|ES| 2:1 9:1 18:1 19:1 130:1 350:1 438:1 792:1 798:1 925:1 927:1 1114:1 1359:1 1474:1 1640:1 1641:1 1642:1 1643:1 1644:1 1645:1 1646:1 1647:1



